CAP is a pragmatic cluster RCT, testing effective- ness in everyday practice by comparing an invitation to attend for population-based PSA testing for prostate cancer (the ProtecT trial intervention arm) with standard UK National Health Service (NHS) care (control arm) in men aged 50–69 ...
Provides information on the toolkits to be provided by the National Health Service (NHS) of Great Britain to help general practitioners counsel male patients about prostate specific antigen te...
In future, CDK12 could also be explored as a genetic weakness that could be targeted by new precision drugs for prostate cancer. Professor Johann de Bono, Regius Professor of Cancer Research at The Institute of Cancer Research, London, said: "Immunotherapy works for a relatively small group of...
A digital pathway for genetic testing in UK NHS patients with cancer: BRCA-DIRECT randomised study internal pilot. J Med Genet. 2022;59(12):1179-1188. doi:10.1136/jmg-2022-108655 PubMedGoogle ScholarCrossref 18. De Silva DL, Stafford L, Skandarajah AR, et al. ...
Reflex mismatch repair immunohistochemistry (MMR IHC) testing for MLH1, PMS2, MSH2 and MSH6 is used to screen for Lynch syndrome. Recently MMR-deficiency (MMRd) has been approved as a pan-cancer predictive biomarker for checkpoint inhibitor therapy, leading to a vast increase in the use of ...
Currently, germline genetic testing of MPT-affected individuals for variants in cancer-predisposition genes (CPGs) is mostly targeted by tumor type. We ascertained pre-assessed MPT individuals (with at least two primary tumors by age 60 years or at least three by 70 years) from genetics centers...
who has received an EPSRC-UKRI Innovation Fellowship for his research, said: "Our study sets out to develop a new prototype treatment system that could improve diagnosis and therapy for head and neck cancers, whilst also significantly lowering costs within the NHS by reducing the need for highly...
The strongest genetic risk factors for ovarian cancer are mutations in the BRCA1/2 genes. Clinical genetic testing for BRCA1/2 gene mutations is currently available as a service on the NHS in the UK to individuals with a 10% or greater chance of carrying a BRCA1/2 mutation [3] including...
Screening for prostate cancer with serum prostate specific antigen (PSA) remains a controversial topic. The UK NHS Executive has issued extensive guidance ... M Lamplugh,P Gilmore,T Quinlan,... - 《Annals of the Royal College of Surgeons of England》 被引量: 42发表: 2006年 ...
BRCA1 and BRCA2 are tumor suppressor genes that have been linked to inherited susceptibility of breast cancer. Germline BRCA1/2 pathogenic or likely pathogenic variants (gBRCAm) are clinically relevant for treatment selection in breast cancer because the